



UroGen Pharma Announces Two Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association 2017 Annual Meeting

May 11, 2017

RAANANA, Israel, May 11, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced today that the Company has been selected for an oral podium presentation and a poster presentation at the upcoming American Urology Association 2017 Annual Meeting in Boston, Massachusetts from May 12 to May 16, 2017.

The oral podium and poster presentations are related to UroGen Pharma's clinical stage uro-oncology product candidates, as detailed below:

Oral podium presentation: PD19-10: The Chemoablative Effect of VesiGel Instillation in Patients with NMIBC – Response Rate and One-Year Durability

Presenting Author: Andrew Lenis, MD MS, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California

Session: Bladder Cancer: Non-Invasive II on Saturday, May 13 from 8:30 am EDT to 8:40 am EDT

Poster presentation based on abstract title: MP98-05: Checkpoint Inhibition with Systemic Anti-Programmed Cell Death Ligand-1 and Intravesical TMX-101 (Vesimune) Decrease Tumor Burden in a Mouse Model of Urothelial Carcinoma

Presenting Author: Andrew T. Lenis MD MS, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California

Session: Bladder Cancer: Basic Research & Pathophysiology on Tuesday, May 16 from 9:30 am EDT to 11:30 am EDT

About UroGen Pharma Ltd.

UroGen Pharma is a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially improving the efficacy and safety profiles of existing drugs. UroGen Pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma's lead product candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade UTUC and bladder cancer. UroGen Pharma is headquartered in Israel and also maintains a corporate office in New York City.

CONTACT: □

Gary Titus, UroGen Pharma Ltd.

689 Fifth Avenue, 14th Floor

New York, NY 10022 □

garyt@urogen.com

646-768-9531 □

Stephanie Carrington, ICR, Inc.

685 Third Avenue, 2nd Floor

New York, NY 10017 □

stephanie.carrington@icrinc.com

646-277-1282



UroGen Pharma